Table 5. Review of Previous Studies of LMR as a Prognostic Factor for Advanced NSCLC [13, 26-28].
| Author (year) | Country | N | Patient treatment | Cut-off | Multivariate analyses |
|||
|---|---|---|---|---|---|---|---|---|
| OS |
PFS |
|||||||
| HR (95% CI) | P | HR (95% CI) | P | |||||
| Lin et al (2014) [13] | China | 370 | Stage IIIB or IV, platinum-based doublet | 4.56 | 0.530 (0.409 - 0.687) | < 0.001 | 0.660 (0.512 - 0.851) | 0.001 |
| Chen et al (2015) [28] | Taiwan | 253 | EGFR mt (+) first-line EGFR-TKIs | 3.29 | 2.36 (1.66 - 3.35) | < 0.001 | 1.71 (1.14 - 2.56) | 0.009 |
| Chang et al (2017) [27] | Taiwan | 490 | Stage IV | 3.1 | 1.844 (1.212 - 1.837) | < 0.001 | NA | NA |
| Our (2017) [26] | Japan | 152 | EGFR mt (+), EGFR-TKIs | 5.09 | 0.88 (0.76 - 1.01) | 0.07 | 1.00 (0.90 - 1.12) | 0.99 |
| Our | Japan | 159 | Stage IIIB or IV, Ad, platinum-based | 1.97 | 0.39 (0.21 - 0.72) | < 0.01 | NA | NA |
Ad: adenocarcinoma; CI: confidence interval; EGFR: epidermal growth factor receptor; HR: hazard ratio; LMR: lymphocyte to monocyte ratio; mt: mutation; NA: not assessed; NSCLC: non-small cell lung cancer; PFS: progression-free survival; OS: overall survival; TKI: tyrosine kinase inhibitor.